Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.47 |
| ▸ | FURIN | P09958 | 2/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.38 |
| ▸ | NPY4R | P50391 | 5/20 | 0.38 |
| ▸ | NPY1R | P25929 | 4/20 | 0.38 |
| ▸ | NPY2R | P49146 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24520454 | 1.00 | FAP (0.47) | FAPFURINNPY5RNPY4RNPY1R | |
| SCHEMBL21649698 | 0.94 | FURIN (0.44) | FAPFURINNPY5RNPY4RNPY1R | |
| SCHEMBL22336596 | 0.94 | FURIN (0.44) | FAPFURINNPY5RNPY4RNPY1R | |
| SCHEMBL27432486 | 0.94 | FAP (0.46) | FAPFURINNPY5RNPY4RNPY1R | |
| SCHEMBL16273799 | 0.94 | NPY4R (0.46) | FAPFURINNPY5RNPY4RNPY1R | |
| SCHEMBL21416485 | 0.94 | FAP (0.44) | FAPFURINNPY5RNPY4RNPY1R | |
| SCHEMBL16266215 | 0.94 | FAP (0.44) | FAPFURINNPY5RNPY4RNPY1R | |
| SCHEMBL16266184 | 0.94 | FAP (0.44) | FAPFURINNPY5RNPY4RNPY1R | |
| SCHEMBL22952275 | 0.94 | FAP (0.44) | FAPFURINNPY5RNPY4RNPY1R | |
| SCHEMBL20808481 | 0.94 | FAP (0.44) | FAPFURINNPY5RNPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019232449-A9 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-24 | — | — | WO | disclosed |
| US-9803002-B2 | Anti-wall teichoic antibodies and conjugates | Genentench, Inc. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9669106-B2 | Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2017-06-06 | — | — | US | disclosed |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20150366985-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20140356375-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140356376-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20120148608-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120034247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7851437-B2 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7829531-B2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20090324621-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366985-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885FURIN 1993/4885NPY5R 3485/4885 |
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | DAD1, DDOST, STT3A | FAP 2680/4885FURIN 342/4885NPY5R 2056/4885 |
| US-20140356375-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885FURIN 1993/4885NPY5R 3485/4885 |
| US-20140356376-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885FURIN 1993/4885NPY5R 3485/4885 |
| US-20120034247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | FAP 2453/4885FURIN 410/4885NPY5R 1587/4885 |
| US-20090324621-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | DAD1, DDOST, STT3A | FAP 2680/4885FURIN 342/4885NPY5R 2056/4885 |
| US-20120148608-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | FAP 2453/4885FURIN 410/4885NPY5R 1587/4885 |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | STS, TST, SCLY | FAP 2854/4885FURIN 469/4885NPY5R 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.